Welcome to

NOK Therapeutics

We are a clinical-stage biotechnology company pioneering a new paradigm in cancer care: safe, practical, and timely natural killer (NK) cell therapies. 

Welcome to

NOK Therpeutics

We are a clinical-stage biotechnology company pioneering a new paradigm in cancer care: safe, practical, and timely natural killer (NK) cell therapies. v

Our Mission &

Vision for the Future

Our mission is simple yet ambitious: to restore the body’s first line of immune defense at the moments when patients need it most.

Vision: To normalize this new category of immunotherapy – cell therapies designed for the precise therapeutic moments when cures are within reach.

NOK's Approach

Filling the Critical Gap in Oncology

NOK Therapeutics was founded to fill a critical gap in oncology with autologous, non-engineered NK cell therapies designed to extend remission, expand access, and integrate seamlessly into standard cancer care.

Addressing Relapse

Our NK cells are designed for patients who relapse despite aggressive frontline therapy.

Expanding Access

Many are excluded from cell therapies due to toxicity, cost, or logistics – our NK cells fill this critical gap.

Seamless Integration

Our NK cell therapies are designed for practical use with outpatient infusions and flexible re-dosing highly feasible.

Led by Industry Veterans

Leadership with combined 50 years in pharmaceutical development and involvement in 45+ FDA approvals.

Robert Lewis

Co-Founder & CEO

Operational leader with 30 FDA approvals and commercialization expertise.

Tamara Jovonovich, PhD

Co-Founder & COO

Strategic scientist integrating experience in research and leadership to advance novel therapies.